CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.73B, above the global median of $1.15B
- PositionReturn on equity is 19.2%, higher than 95% of its Medical Devices peers (median 2.8%)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.35%Above 5Y avg (1.19%)
Annual Rate
CNY 0.60Paid annual
Payout Ratio
31.6%Sustainable
Payback Period
73.7 yr
Last Ex-Dividend
Jul 7, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
18.38BCNY2.73B · vs all stocks (USD)
Trailing P/E
28.38xvs Medical Devices peers
Revenue (TTM)
2.69BCNY399.82M · vs all stocks (USD)
Profit Margin
23.89%vs Medical Devices peers
Beta
0.0690xvs all stocks
52-Week Change
-24.10%vs all stocks
Market Capitalization
18.38BCNY2.73B · vs all stocks (USD)
Enterprise Value
16.51BCNY2.45B · vs all stocks (USD)
Trailing P/E
28.38xvs Medical Devices peers
Forward P/E
35.59xvs Medical Devices peers
Price to Sales (TTM)
6.90xvs Medical Devices peers
Price to Book (MRQ)
4.92xvs Medical Devices peers
Enterprise to Revenue
6.13xvs Medical Devices peers
Enterprise to EBITDA
21.40xvs Medical Devices peers
Gross Margin
74.16%vs Medical Devices peers
Profit Margin
23.89%vs Medical Devices peers
Operating Margin
29.57%vs Medical Devices peers
Return on Assets (TTM)
8.48%vs Medical Devices peers
Return on Equity (TTM)
19.16%vs Medical Devices peers
Revenue (TTM)
2.69BCNY399.82M · vs all stocks (USD)
Revenue per Share (TTM)
6.62CNYUpdated Aug 20, 2026Quarterly Revenue Growth
16.60%vs Medical Devices peers
Gross Profit (TTM)
1.87BCNY277.32M · vs all stocks (USD)
EBITDA (TTM)
743.75MCNY110.46M · vs all stocks (USD)
Net Income (TTM)
643.10MCNY95.51M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.20%vs Medical Devices peers
Operating Cash Flow (TTM)
875.77MCNY130.07M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
574.97MCNY85.39M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.35%vs all stocks
5-Year Average Dividend Yield
1.19%vs all stocks
Payout Ratio
31.65%vs Medical Devices peers
Minority Interest (Equity)
115.24MCNYFY2025 · Dec 31, 2025Revenue
2.60BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
767.19MCNYFY2025 · Dec 31, 2025Gross Profit
1.83BCNYFY2025 · Dec 31, 2025Operating Income
719.07MCNY106.80M · vs all stocks (USD)
Pre-tax Income
730.04MCNYFY2025 · Dec 31, 2025Income Tax Expense
93.17MCNYFY2025 · Dec 31, 2025Net Income
636.88MCNYFY2025 · Dec 31, 2025EBIT
736.22MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
889.83MCNYFY2025 · Dec 31, 2025Research & Development
331.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
470.18MCNYFY2025 · Dec 31, 2025Other Operating Expenses
36.48MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
27.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.18MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.47CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.47CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.91MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.91MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
636.88MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-37.25MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
549.67MCNYFY2025 · Dec 31, 2025Free Cash Flow
417.46MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
128.00MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
636.88MCNYFY2025 · Dec 31, 2025Other Non-cash Items
78.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-58.54MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-107.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-132.21MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.75BCNYFY2025 · Dec 31, 2025Sale of Investments
1.45BCNYFY2025 · Dec 31, 2025Other Investing Activity
-246.22MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-679.66MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
94.87MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-167.84MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-214.36MCNYFY2025 · Dec 31, 2025Other Financing Charges
42.81MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-244.51MCNYFY2025 · Dec 31, 2025Shares Outstanding
414.02MSharesUpdated Aug 20, 2026Float Shares
67.87MSharesUpdated Aug 20, 2026% Held by Insiders
82.84%vs all stocks
% Held by Institutions
3.92%vs all stocks
Total Cash (MRQ)
1.84BCNY273.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.50CNYUpdated Aug 20, 2026Total Debt (MRQ)
359.98MCNY53.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0934xvs Medical Devices peers
Current Ratio (MRQ)
4.23xvs Medical Devices peers
Book Value per Share (MRQ)
9.11CNYUpdated Aug 20, 2026Total Assets
4.92BCNY731.35M · vs all stocks (USD)
Total Current Assets
3.34BCNYFY2025 · Dec 31, 2025Total Liabilities
1.24BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.59BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
360.81MCNYFY2025 · Dec 31, 2025Total Current Liabilities
878.18MCNYFY2025 · Dec 31, 2025Cash
1.22BCNYFY2025 · Dec 31, 2025Cash Equivalents
16.17KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.22BCNYFY2025 · Dec 31, 2025Other Short-term Investments
496.97MCNYFY2025 · Dec 31, 2025Accounts Receivable
302.87MCNYFY2025 · Dec 31, 2025Inventory
1.23BCNYFY2025 · Dec 31, 2025Accounts Payable
266.64MCNYFY2025 · Dec 31, 2025Short-term Debt
12.36MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.98MCNYFY2025 · Dec 31, 2025Long-term Debt
301.04MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.80MCNYFY2025 · Dec 31, 2025Common Stock (Book)
414.02MCNYFY2025 · Dec 31, 2025Retained Earnings
1.93BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.69BCNY547.33M · vs all stocks (USD)
Treasury Stock
166.61MCNYFY2025 · Dec 31, 202552-Week Low
39.58CNYUpdated Aug 20, 202652-Week High
59.99CNYUpdated Aug 20, 202652-Week Change
-24.10%vs all stocks
Beta
0.0690xvs all stocks
50-Day MA
43.79CNYUpdated Aug 20, 2026200-Day MA
45.48CNYUpdated Aug 20, 2026Avg 10-Day Volume
2.48MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.59MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.58CNYUpdated Aug 20, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 19.2%, higher than 95% of its Medical Devices peers (median 2.8%)Significant
Return on equity: 0.19Industry median: 0.03Industry P95: 0.18Peers compared: 59.00
Financial Health
Altman Z-Score 11.07: safe zoneNotable
Altman Z-Score: 11.07
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.73B, above the global median of $1.15BNotable
Market cap (USD): 2,730,163,860.122Global Median: 1,146,734,693.424
Levered free cash flow is $85.39M, above the global median of $16.24MNotable
Levered free cash flow (USD): 85,394,608.561Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Garmin Ltd.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios Elevated
K92 Mining Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios Elevated
United States Lime & Minerals Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios Elevated